Weekly Research Analysts’ Ratings Changes for Liquidia (LQDA)

Liquidia (NASDAQ: LQDA) recently received a number of ratings updates from brokerages and research firms:

• 10/15/2026 – Liquidia was given a new $65.00 price target by Royal Bank Of Canada.
• 10/15/2026 – Liquidia had its price target raised by HC Wainwright from $58.00 to $65.00. They now have a “buy” rating on the stock.
• 10/14/2026 – Liquidia had its price target raised by Wells Fargo & Company from $30.00 to $33.00. They now have an “equal weight” rating on the stock.
• 10/14/2026 – Liquidia was upgraded by Lifesci Capital from “hold” to “outperform”. They now have a $59.00 price target on the stock.
• 10/14/2026 – Liquidia was upgraded by BTIG Research from “neutral” to “buy”. They now have a $70.00 price target on the stock.
• 10/14/2026 – Liquidia had its price target lowered by Needham & Company LLC from $72.00 to $58.00. They now have a “buy” rating on the stock.
• 10/8/2026 – Liquidia had its “outperform” rating reaffirmed by Raymond James Financial, Inc..
• 10/3/2026 – Liquidia was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/2/2026 – Liquidia was given a new $58.00 price target by Wedbush.
• 10/2/2026 – Liquidia had its “equal weight” rating reaffirmed by Wells Fargo & Company. They now have a $30.00 price target on the stock, down from $108.00.
• 10/2/2026 – Liquidia had its price target lowered by HC Wainwright from $130.00 to $58.00. They now have a “buy” rating on the stock.
• 10/1/2026 – Liquidia was downgraded by Raymond James Financial, Inc. from “strong-buy” to “outperform”. They now have a $53.00 price target on the stock, down from $106.00.
• 10/1/2026 – Liquidia had its “neutral” rating reaffirmed by Citigroup Inc..
• 10/1/2026 – Liquidia was downgraded by BTIG Research from “buy” to “neutral”.
• 10/1/2026 – Liquidia was downgraded by Wells Fargo & Company from “overweight” to “equal weight”. They now have a $30.00 price target on the stock, down from $108.00.
• 10/1/2026 – Liquidia was upgraded by Jefferies Financial Group Inc. to “strong-buy”.
• 10/1/2026 – Liquidia had its price target lowered by Needham & Company LLC from $110.00 to $72.00. They now have a “buy” rating on the stock.
• 9/22/2026 – Liquidia was upgraded by Weiss Ratings from “sell (d-)” to “hold (c)”.
• 9/22/2026 – Liquidia was downgraded by Zacks Research from “hold” to “strong sell”.
• 9/20/2026 – Liquidia was upgraded by Wall Street Zen from “hold” to “buy”.
• 9/12/2026 – Liquidia was downgraded by Wall Street Zen from “buy” to “hold”.

Insider Buying and Selling at Liquidia

In related news, insider Rajeev Saggar sold 50,000 shares of Liquidia stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $74.06, for a total transaction of $3,703,000.00. Following the transaction, the insider directly owned 142,265 shares of the company’s stock, valued at $10,536,145.90. The trade was a 26.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Stephen Bloch sold 235,477 shares of the business’s stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $27.13, for a total transaction of $6,388,491.01. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 666,598 shares of company stock valued at $34,796,390. Corporate insiders own 25.60% of the company’s stock.

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with pulmonary hypertension and other serious cardiopulmonary diseases. The company is headquartered in Research Triangle Park, North Carolina, and uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition for inhaled and injectable medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder formulation of treprostinil delivered through a proprietary inhaler.